TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38762720
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI)
Study: 38699346
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment without phone-based MI
Study: 38762720
Drug: Duloxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine monotherapy
Study: 38699828
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole
Study: 38699939
Drug: Cedirogant 75
Normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cedirogant 75 mg
Study: 38699939
Drug: Cedirogant 150
Normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cedirogant 150 mg
Study: 38699939
Drug: Cedirogant 375
Normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cedirogant 375 mg
Study: 38700579
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of rh-endostatin (210 mg) over a period of 120 hours combined with platinum-based doublet chemotherapy (pemetrexed or paclitaxel) in 21-day cycles.
Study: 38700630
Drug: 10-day bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day bismuth-containing quadruple therapy
Study: 38701812
Drug: Hydroxyurea (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (17.5 ± 2.5 mg/kg per day for 6 months, followed by dose escalation up to 20-35 mg/kg per day)
Study: 38701812
Drug: Hydroxyurea dose
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea dose escalation to MTD with dose optimisation
Study: 38701881
Drug: Withdrawing neurohormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawing neurohormonal blockers
Study: 38701881
Drug: Neurohormonal blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurohormonal blockers (control group)
Study: 38701961
Drug: Down Sizing
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Down Sizing Strategy (HANGZHOU Solution)
Study: 38702761
Drug: SABR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABR with MRI guided focal dose intensification
Study: 38702828
Drug: Neoadjuvant niraparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant niraparib treatment
Study: 38702828
Drug: Neoadjuvant platinum-taxane
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant platinum-taxane doublet chemotherapy
Study: 38702961
Drug: Sodium channel
Normalized name: Sodium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium channel blockers (SCBs) - flecainide or propafenone
Study: 38703010
Drug: Nirogacestat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirogacestat (150 mg, twice-daily, continuous 28-day cycles)
Study: 38703010
Drug: Nirogacestat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirogacestat (150 mg)
Study: 38703782
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with SARS-CoV-2 in a stepwise dose escalation controlled human infection model (CHIM) with a dose of 1×10
Study: 38703993
Drug: FDA-approved anti-angiogenic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved anti-angiogenic agents combined with immunotherapy and nanocarrier-mediated targeted therapy
Study: 38705163
Drug: Artemether-lumefantrine with
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine with primaquine (0.25 mg/kg)
Study: 38705163
Drug: Sulfadoxine-pyrimethamine plus
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine (1.66 mg/kg)
Study: 38705167
Drug: Seralutinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seralutinib (60 mg twice daily for 2 weeks, then increased to 90 mg twice daily as tolerated)
Study: 38705167
Drug: Placebo (dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dry powder inhaler, twice daily for 24 weeks)
Study: 38705804
Drug: Ad26.COV2.S (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S (various dose levels)
Study: 38705804
Drug: Ad26.COV2.S (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S (single dose schedule)
Study: 38706247
Drug: Cadonilimab 10
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10 mg/kg every three weeks (Q3 W) for up to 24 months until progressive disease (PD) or adverse events (AE) discovery.
Study: 38706390
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (one intravenous injection)
Study: 38706390
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one injection of saline solution)
Study: 38706610
Drug: LMB-100 (30-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMB-100 (30-minute infusion on days 4, 6, and 8 at doses of 100 and 140 µg/kg) + tofacitinib (10 mg BID for the first 10 days of the cycle)
Study: 38706611
Drug: QUS-radiomics model-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUS-radiomics model-guided adaptive chemotherapy (experimental arm)
Study: 38706726
Drug: Dose intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose intensified sRT (64 Gy vs 70 Gy)
Study: 38707876
Drug: Lateral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral Suspension (LS)
Study: 38708017
Drug: Group hypnosis
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group hypnosis program for stress reduction (5 weekly sessions) plus 5 hypnosis audio recordings and an educational booklet on coping with stress
Study: 38708072
Drug: PWP co-facilitated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWP co-facilitated intervention delivered over six weekly sessions
Study: 38708959
Drug: Non-pooled, multidonor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pooled, multidonor faecal microbiota transplantation (FMT) for 4 weeks, delivered daily by enema for 2 weeks, followed by every second day for 2 weeks.
Study: 38709006
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir with oral lead-in (OLI)
Study: 38709006
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir without oral lead-in (OLI)
Study: 38709212
Drug: Sequential dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential dosing of sacituzumab govitecan (SG) followed by talazoparib (TZP)
Study: 38709212
Drug: Concurrent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent dosing of sacituzumab govitecan (SG) with talazoparib (TZP)
Study: 38709220
Drug: FAP-IL2v 10
Normalized name: AVA-6000 (FAP-activated doxorubicin prodrug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAP-IL2v 10 mg plus atezolizumab 1,200 mg intravenously every 3 weeks
Study: 38709220
Drug: FAP-IL2v weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAP-IL2v weekly for 4 weeks and then every 2 weeks plus atezolizumab 840 mg intravenously every 2 weeks
Study: 38709228
Drug: EDIT-101 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDIT-101 (low dose)
Study: 38709228
Drug: EDIT-101 (intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDIT-101 (intermediate dose)
Study: 38709228
Drug: EDIT-101 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDIT-101 (high dose)
Study: 38709456
Drug: Intraoperative haemoadsorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery
Study: 38709500
Drug: Cytisinicline, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline, 3 mg, taken 3 times daily (n=107)
Study: 38709986
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg once daily for 6 weeks, titrated to 10 mg once daily for 18 weeks)
Study: 38709999
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) selected by noncontrast CT (NCCT)
Study: 38710185
Drug: Garadacimab 200
Normalized name: Garadacimab
DrugBank: Garadacimab (DB15629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garadacimab 200 mg once monthly
Study: 38710185
Drug: Garadacimab 600
Normalized name: Garadacimab
DrugBank: Garadacimab (DB15629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garadacimab 600 mg once monthly
Study: 38710187
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg every 3 weeks by intravenous infusion)
Study: 38710192
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster subunit vaccine (0.5 mL intramuscular injection) at weeks 0 and 8
Study: 38710192
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mL intramuscular injection) at weeks 0 and 8
Study: 38710192
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster subunit vaccine
Study: 38710269
Drug: 1-g conjugated
Normalized name: estrogens, conjugated (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g conjugated estrogen cream (0.625 mg/g), inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Study: 38710269
Drug: Placebo cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Study: 38710269
Drug: 1-g conjugated
Normalized name: estrogens, conjugated (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g conjugated estrogen cream (0.625 mg/g)
Study: 38710325
Drug: Preoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative ketamine 0.5 mg/kg intravenous bolus
Study: 38710445
Drug: HSP+ (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSP+ (45 g HSP + 5 g HSP-derived bioactive peptides/d)
Study: 38710445
Drug: HSP (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSP (50 g HSP/d)
Study: 38710445
Drug: Casein (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (50 g casein/d)
Study: 38710487
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg once daily (QD) 3 days on, 4 days off (160 3/4)
Study: 38710487
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg QD 3 days on, 4 days off (120 3/4)
Study: 38710487
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg QD 3 days on, 4 days off, 2 weeks on, 1 week off (160 3/4, 2/1w)
Study: 38710537
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate sodium (137 mEq/L)
Study: 38710537
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate sodium (140 mEq/L)
Study: 38710539
Drug: Traditional systemic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional systemic treatment
Study: 38710539
Drug: Nonsystemic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsystemic treatment
Study: 38710583
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive non-surgical therapy (MINST)
Study: 38710920
Drug: Nuvastatic™ 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuvastatic™ 1000 mg thrice daily for 9 weeks
Study: 38710996
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine (650 mg/m² twice daily for 1 year)
Study: 38711253
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus azacitidine (75 mg/m²)
Study: 38712176
Drug: Consolidation doublet
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long course chemoradiation (LCRT)
Study: 38712176
Drug: Consolidation triplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long course chemoradiation (LCRT)
Study: 38712567
Drug: TXT (anti-hypotensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXT (anti-hypotensive therapy)
Study: 38712616
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccines
Study: 38713205
Drug: Surufatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks)
Study: 38713500
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for PVCs, delivered over 10 weeks via videoconference with online text-based information and homework assignments.
Study: 38713500
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for PVCs
Study: 38713595
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (CAR T-cell therapy)
Study: 38713888
Drug: Mass spectrometry
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass spectrometry (MS) assessment of measurable residual disease (MRD) negativity during posttransplant therapy
Study: 38713894
Drug: Synthetic long
Normalized name: Human Papilloma Virus (HPV) Type 16 E6/E7 Synthetic Long Peptide (SLP) Vaccine Component L-3972-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic long peptide vaccines targeting predicted high-quality neoantigens
Study: 38714422
Drug: topical promestriene
Normalized name: promestriene
DrugBank: Promestriene (DB12487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical promestriene for 90 days (n=17)
Study: 38714422
Drug: fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: fractional CO2 laser treatment (n=24)
Study: 38714422
Drug: microablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: microablative fractional radiofrequency treatment (n=21)
Study: 38714786
Drug: THC (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (10-80 mg, individually dosed)
Study: 38714924
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1% lidocaine
Study: 38714999
Drug: Selenium yeast
Normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium yeast (200 µg/day) and coenzyme Q
Study: 38715140
Drug: Autologous adipose
Normalized name: Autologous adipose derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation (2 infusions of 100 million cells i.v)
Study: 38715621
Drug: Immune tolerance
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune tolerance induction (ITI) therapy with bortezomib, rituximab, methotrexate, and intravenous immunoglobulin over 6 months
Study: 38715621
Drug: Immune tolerance
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune tolerance induction (ITI) therapy
Study: 38716419
Drug: Ciprofol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol (0.4 mg/kg for induction and 0.2 mg/kg for maintenance)
Study: 38716419
Drug: Propofol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0 mg/kg for induction and 1.0 mg/kg for maintenance)
Study: 38717075
Drug: D3S-001, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3S-001, a next-generation GDP-bound G12C inhibitor
Study: 38717075
Drug: Sotorasib and
Normalized name: sotorasib
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib and adagrasib (first-generation KRAS G12C inhibitors)
Study: 38717556
Drug: No beta
Normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta blockers
Study: 38717773
Drug: Rapid procedure
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid procedure (RP): 1 day of buprenorphine at minimum necessary dose, 1 opioid-free day, ascending low doses of oral naltrexone and adjunctive medications
Study: 38717773
Drug: Standard procedure
Normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure (SP): approximately 5-day buprenorphine taper followed by a 7- to 10-day opioid-free period
Study: 38717861
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (IC) 3+7
Study: 38717993
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab with chemotherapy
Study: 38717997
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (three sessions weekly for 8 weeks)
Study: 38718169
Drug: Daily Examen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Examen prayer practice
Study: 38718683
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AI) intake
Study: 38718683
Drug: Multivariable analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariable analysis of ET intake timing and ET agent
Study: 38718923
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) and Artificial Intelligence (AI) model
Study: 38718924
Drug: Total Iodine
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Iodine Excretion (TIE)
Study: 38718924
Drug: Urinary Iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary Iodine Excretion Rate (UIER)
Study: 38718924
Drug: Breast Milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast Milk Iodine Excretion Rate (BMIER)
Study: 38718924
Drug: Effect of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of TII on BMIER when TII <120 μg/d
Study: 38719277
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (carboplatin and paclitaxel in a 3 weekly scheme) followed by surgery
Study: 38719277
Drug: Primary chemoradiation
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemoradiation (tumor dose of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for 6 weeks)
Study: 38719280
Drug: Androgenic anabolic
Normalized name: ANDROGENS/ANABOLICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgenic anabolic steroids (AAS) use
Study: 38719313
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (CaD) 500 mg, two capsules two times per day for 7 days
Study: 38719313
Drug: Placebo (mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mannitol 312.5 mg), two matching capsules two times per day for 7 days
Study: 38719544
Drug: YSCH-01 (Recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: YSCH-01 (Recombinant L-IFN adenovirus)
Study: 38719803
Drug: Primaquine (0.25-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (0.25-1 mg base/kg once daily given to the mother for 1-14 days)
Study: 38720363
Drug: SBIRT (Screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT (Screening, Brief Intervention and Referral to Treatment) delivered by trained lay health workers, followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers.
Study: 38720383
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days
Study: 38720383
Drug: Adjunctive corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroids (prednisone 1.5 mg/kg/day) for the first 14 days of TB treatment
Study: 39622823
Drug: Standard tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tuberculosis treatment
Study: 38720661
Drug: Cafedrine/theodrenaline (C/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafedrine/theodrenaline (C/T) combination (20:1)
Study: 38720913
Drug: 4-week low-frequency
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week low-frequency rTMS targeting the right dorsolateral prefrontal cortex (rDLPFC) + treatment as usual (TAU) (n = 25)
Study: 38720913
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation + treatment as usual (TAU) (n = 25)
Study: 38720913
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) only (for low FCR group)
Study: 38720913
Drug: Post-treatment fMRI
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment fMRI scan